RobertHauserMD

Neurology • Tampa, FL

Movement Disorder

Professor of Neurology, University S Fla College of Medicine

Join to view full profile

Dr. Hauser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hauser's full profile

Already have an account?

Office
12901 Bruce B Downs Blvd
Tampa, FL 33612
Phone+1 813-844-4455

Fax+1 813-844-4456

Summary

Dr. Robert Hauser is Director of the Parkinson's Disease and Movement Disorders Center of the University of South Florida. He received his medical degree from Temple University School of Medicine and has been in practice 31 years. He specializes in Parkinson's disease and is an expert in clinical research to develop new treatments for Parkinson's disease and related disorders. He also performs Botox injections for cervical dystonia, blepharospasm, and hemifacial spasm. He has published over 300 peer reviewed articles and lectures frequently at scientific meetings.

Education & Training

Eastern Virginia Medical SchoolResidency, Neurology, 1983 - 1988
Albert Einstein Medical CenterInternship, Transitional Year, 1982 - 1983
Lewis Katz School of Medicine at Temple UniversityClass of 1982

Certifications & Licensure

FL State Medical License 1989 - 2026
CA State Medical License 1986 - 1992
MI State Medical License 1988 - 1990
PA State Medical License 1988 - 1990
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly

Clinical Trials

Keppra for Cervical Dystonia Start of enrollment: 2005 Nov 01
Terminated
Phase 2
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease Start of enrollment: 2009 Mar 01
Unknown status
Phase 3
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Start of enrollment: 2010 Jun 01
Completed
Phase 2
Glutathione (GSH) In The Treatment of Parkinson's Disease Start of enrollment: 2003 Sep 01
Completed
Phase 2
Parkinson's Foundation Quality Improvement Initiative Start of enrollment: 2009 Jul 01
Completed
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease Start of enrollment: 2013 Mar 01
Terminated
Phase 2
A Study to Examine APL-130277 in Patients With Parkinson's Disease Start of enrollment: 2014 Aug 31
Completed
Phase 2
A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients Start of enrollment: 2016 Mar 01
Unknown status
Phase 3
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis Start of enrollment: 2016 Dec 31
Completed
Phase 2
A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness Start of enrollment: 2017 Jan 01
Completed
Phase 2
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation Start of enrollment: 2017 May 11
Completed
Phase 1, Phase 2
Fixed-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2019 Dec 13
Active, not recruiting
Phase 3
Roles: Contact
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations Start of enrollment: 2020 Oct 27
Completed
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Samuel Frank, Karen E Anderson, Hubert H Fernandez, Robert A Hauser, Daniel O Claassen
Neurology and Therapy. 2024-12-01
9 citations
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Ana Westenberger, Volha Skrahina, Tatiana Usnich, Christian Beetz, Eva-Juliane Vollstedt
Brain. 2024-08-01
Current use of neurotoxins for alleviating symptoms of cervical dystonia.
Stephen Aradi, Robert A Hauser
Expert Review of Neurotherapeutics. 2024-08-01

Journal Articles

Therapeutic Strategies for Parkinson Disease: Beyond Dopaminergic Drugs
Robert Hauser, MD, Nature
Deutetrabenazine for Treatment of Involuntary Movements in Patients with Tardive Dyskinesia (AIM-TD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
Hubert H Fernandez, Robert A Hauser, The Lancet

Press Mentions

FDA Approves Vyalev for Advanced Parkinson's DiseaseOctober 23rd, 2024
FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s DiseaseOctober 22nd, 2024
Injectable Drug to Ease Advanced Parkinson's Disease Symptoms Approved by FDAOctober 17th, 2024
Join now to see all